NDAINJECTIONINJECTABLEPriority Review
Approved
Mar 1967
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Fluphenazine enanthate is a long-acting injectable antipsychotic belonging to the phenothiazine class, approved for schizophrenia and other psychotic disorders. Administered intramuscularly, it provides sustained dopamine D2 antagonism over weeks, reducing the need for daily oral medication and improving adherence in patients with severe mental illness.
LOE Approaching
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30%), commercial teams are likely focused on retention and cost management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Prolixin Enanthate offers limited career advancement opportunities given its LOE-approaching status and minimal linked job openings. Roles are primarily focused on defending market share and optimizing costs rather than driving growth or innovation.
Brand ManagerField Sales Representative
Worked on PROLIXIN ENANTHATE at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.